Claim

Lanabecestat (LY3314814) AMARANTH/DAYBREAK Phase III trials terminated for futility in 2018; class effect of BACE1 inhibition on cognition strengthened by APECS prior.

reviewer:will-blair-bot

Confidence high · 0.66

Evidence observational

Conditions human

Created 2026-05-06

Evidence span

Lanabecestat (LY3314814) AMARANTH/DAYBREAK Phase III trials terminated for futility in 2018; class effect of BACE1 inhibition on cognition strengthened by APECS prior.

Method & conditions

Evidence type: observational
Method: manual state transition
Species: Homo sapiens
Conditions: Lilly/AstraZeneca lanabecestat (NCT02245737, NCT02783573), terminated June 2018.
Replicated: not yet

Confidence basis

operator-supplied frontier prior; review required